# MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma

Source: https://onco.cc/trials/nct07036380/  
OnCo record `nct07036380` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of durvalumab, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by Centre Hospitalier Universitaire de Besancon, now recruiting.

## Summary

MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma is a phase 2, randomised interventional study registered as NCT07036380 by Centre Hospitalier Universitaire de Besancon, with a registry enrolment figure of 75 participants, started 2025-12-22 and due to reach its primary completion in 2028-11. Interventions recorded: MP0317 + Gemcitabine + Cisplatine + Durvalumab, CT-Scan, Gemcitabine + Cisplatin + Durvalumab. Conditions listed: Advanced Biliary Tract Carcinoma. Gallbladder cancer is named in the registry entry: "2. Histologically confirmed biliary tract carcinoma: intra/extrahepatic cholangiocarcinoma (note that gallbladder carcinoma are not eligible)". Sites: France. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: TACTIC
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT07036380
- Phase: 2
- Setting: MP0317, a Tumor Targeting FAP Dependent CD40 Agonist DARPin, in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma: a Radnomized Non-comparative Proof of Concept Phase II Study
- Sponsor: Centre Hospitalier Universitaire de Besancon
- Enrolled: 75

## Sources

- ClinicalTrials.gov NCT07036380: https://clinicaltrials.gov/study/NCT07036380

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Extrahepatic cholangiocarcinoma (perihilar and distal)](https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct07036380.json